Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):156–161. doi: 10.1038/bjc.1993.305

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

D N Poller 1, D R Snead 1, E C Roberts 1, M Galea 1, J A Bell 1, A Gilmour 1, C W Elston 1, R W Blamey 1, I O Ellis 1
PMCID: PMC1968326  PMID: 8100443

Abstract

The expression of oestrogen receptor protein (ER) was examined in 151 cases of symptomatic or screening detected pure ductal carcinoma in situ (DCIS) of the breast by immunocytochemical assay (ERICA), in formalin-fixed paraffin-embedded tissue, with the monoclonal antibody H 222 (Abbott). Forty-eight tumours (31.8%) of cases were ER positive. Twenty-seven (17.9%) of cases showed high level ER expression and 21 (13.9%) of cases showed low level ER immunoreactivity. Significant associations of positive tumour ER immunoreactivity and non-comedo architecture chi 2 = 6.76; (d.f. = 1): P < 0.001, small cell size chi 2 = 4.49; (d.f. = 1): P = 0.034, higher S-phase fraction chi 2 = 4.71; (d.f. = 1): P = 0.03 and lack of c-erbB-2 protein overexpression chi 2 = 7.96; (d.f. = 1): P < 0.01 were identified. No significant associations of ER expression and patient age, histological grade of necrosis in DCIS, or DNA ploidy were found. ER expression is detectable in less than one third of symptomatic and screening detected cases of DCIS, implying that endocrine therapy of DCIS may be a more appropriate form of management for morphological subtypes of DCIS which show higher rates of oestrogen receptor expression, particularly those of non-comedo and small cell type.

Full text

PDF
156

Images in this article

158Figure 1
on p.158

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aasmundstad T. A., Haugen O. A., Johannesen E., Høe A. L., Kvinnsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol. 1992 Feb;45(2):125–129. doi: 10.1136/jcp.45.2.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baisch H., Göhde W., Linden W. A. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 1975 Jun 13;12(1):31–39. doi: 10.1007/BF02339807. [DOI] [PubMed] [Google Scholar]
  3. Barnes R., Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 1990 Nov;94(5):533–537. doi: 10.1093/ajcp/94.5.533. [DOI] [PubMed] [Google Scholar]
  4. Bur M. E., Zimarowski M. J., Schnitt S. J., Baker S., Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992 Mar 1;69(5):1174–1181. doi: 10.1002/cncr.2820690518. [DOI] [PubMed] [Google Scholar]
  5. Cheng L., Binder S. W., Fu Y. S., Lewin K. J. Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest. 1988 Mar;58(3):346–353. [PubMed] [Google Scholar]
  6. Fentiman I. S. Ductal carcinoma in situ. BMJ. 1992 May 16;304(6837):1261–1262. doi: 10.1136/bmj.304.6837.1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fentiman I. S. Treatment of screen detected ductal carcinoma in situ: a silver lining within a grey cloud? Br J Cancer. 1990 Jun;61(6):795–796. doi: 10.1038/bjc.1990.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Giri D. D., Dundas S. A., Nottingham J. F., Underwood J. C. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989 Dec;15(6):575–584. doi: 10.1111/j.1365-2559.1989.tb01623.x. [DOI] [PubMed] [Google Scholar]
  9. Graham D. M., Jin L., Lloyd R. V. Detection of estrogen receptor in paraffin-embedded sections of breast carcinoma by immunohistochemistry and in situ hybridization. Am J Surg Pathol. 1991 May;15(5):475–485. doi: 10.1097/00000478-199105000-00008. [DOI] [PubMed] [Google Scholar]
  10. Hedley D. W., Friedlander M. L., Taylor I. W. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry. 1985 Jul;6(4):327–333. doi: 10.1002/cyto.990060409. [DOI] [PubMed] [Google Scholar]
  11. Locker A. P., Horrocks C., Gilmour A. S., Ellis I. O., Dowle C. S., Elston C. W., Blamey R. W. Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg. 1990 May;77(5):564–567. doi: 10.1002/bjs.1800770533. [DOI] [PubMed] [Google Scholar]
  12. Lovekin C., Ellis I. O., Locker A., Robertson J. F., Bell J., Nicholson R., Gullick W. J., Elston C. W., Blamey R. W. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991 Mar;63(3):439–443. doi: 10.1038/bjc.1991.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Malafa M., Chaudhuri B., Thomford N. R., Chaudhuri P. K. Estrogen receptors in ductal carcinoma in situ of breast. Am Surg. 1990 Jul;56(7):436–439. [PubMed] [Google Scholar]
  14. McCarty K. S., Jr, Miller L. S., Cox E. B., Konrath J., McCarty K. S., Sr Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716–721. [PubMed] [Google Scholar]
  15. Meyer J. S. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat. 1986;7(3):171–180. doi: 10.1007/BF01806247. [DOI] [PubMed] [Google Scholar]
  16. Nicholson R. I., Bouzubar N., Walker K. J., McClelland R., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27(7):908–913. doi: 10.1016/0277-5379(91)90145-4. [DOI] [PubMed] [Google Scholar]
  17. Nowell P. C. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–28. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  18. Paterson D. A., Reid C. P., Anderson T. J., Hawkins R. A. Assessment of oestrogen receptor content of breast carcinoma by immunohistochemical techniques on fixed and frozen tissue and by biochemical ligand binding assay. J Clin Pathol. 1990 Jan;43(1):46–51. doi: 10.1136/jcp.43.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pertschuk L. P., Eisenberg K. B., Carter A. C., Feldman J. G. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer. 1985 Apr 1;55(7):1513–1518. doi: 10.1002/1097-0142(19850401)55:7<1513::aid-cncr2820550717>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  20. Raymond W. A., Leong A. S. Oestrogen receptor staining of paraffin-embedded breast carcinomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses. J Pathol. 1990 Apr;160(4):295–303. doi: 10.1002/path.1711600405. [DOI] [PubMed] [Google Scholar]
  21. Remmele W., Hildebrand U., Hienz H. A., Klein P. J., Vierbuchen M., Behnken L. J., Heicke B., Scheidt E. Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127–147. doi: 10.1007/BF00708323. [DOI] [PubMed] [Google Scholar]
  22. Robertson J. F., Bates K., Pearson D., Blamey R. W., Nicholson R. I. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer. 1992 May;65(5):727–730. doi: 10.1038/bjc.1992.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ronay G., Sponsel N., Tulusan A. H. Duktales Carcinoma in situ (DCIS): Steroidrezeptoren und Proliferationskinetik. Pathologe. 1990 Nov;11(6):327–331. [PubMed] [Google Scholar]
  24. Shintaku I. P., Said J. W. Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Use of DNase pretreatment to enhance sensitivity of the reaction. Am J Clin Pathol. 1987 Feb;87(2):161–167. doi: 10.1093/ajcp/87.2.161. [DOI] [PubMed] [Google Scholar]
  25. Todd J. H., Dowle C., Williams M. R., Elston C. W., Ellis I. O., Hinton C. P., Blamey R. W., Haybittle J. L. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987 Oct;56(4):489–492. doi: 10.1038/bjc.1987.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tzukerman M., Zhang X. K., Hermann T., Wills K. N., Graupner G., Pfahl M. The human estrogen receptor has transcriptional activator and repressor functions in the absence of ligand. New Biol. 1990 Jul;2(7):613–620. [PubMed] [Google Scholar]
  27. Venter D. J., Tuzi N. L., Kumar S., Gullick W. J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 1987 Jul 11;2(8550):69–72. doi: 10.1016/s0140-6736(87)92736-x. [DOI] [PubMed] [Google Scholar]
  28. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  29. Wilbur D. C., Willis J., Mooney R. A., Fallon M. A., Moynes R., di Sant'Agnese P. A. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol. 1992 Jan;5(1):79–84. [PubMed] [Google Scholar]
  30. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES